OHS and OSAHS Flashcards
Diagnosis of OHS. (Harrison’s 19th edition, pp 1723)
BMI >/= 30kg/m2
PaCO2 >/= 45mmHg in the absence of other known causes of hypercapnia
Number of apneas plus hypopneas per hour of sleep. (Harrison’s 19th edition, pp 1725)
Apnea-Hypopanea Index (AHI)
Number of apneas plus hypopneas plus RERAs per hour of sleep. (Harrison’s 19th edition, pp 1725)
Respiratory Disturbance Index (RDI)
A partially obstructed breath that does not meet the criteria for hypoapnea but provides evidence of increasing inspiratory effort (usually through pleural pressure monitoring) puncturated by an arousal. (Harrison’s 19th edition, pp 1725)
Respiratory Effort-Related Arousal (RERA)
Cessation of airflow for >/= 10 sec during sleep. (Harrison’s 19th edition, pp 1725)
Apnea
Obstructive = with persistence respiratory effort
Central = absence of respiratory effort
Mild OSAHS. (Harrison’s 19th edition, pp 1725)
AHI of 5-14 events/hr
Moderate OSAHS. (Harrison’s 19th edition, pp 1725)
AHI of 15-29 events/hr
Severe OSAHS. (Harrison’s 19th edition, pp 1725)
AHI of >/= 30 events/hr
A partially obstructed breath, typically within a hypopnea or RERA, identified by a flattened or “scooped-out” inspiratory flow shape. (Harrison’s 19th edition, pp 1725)
Flow limited breath
A 30% reduction in airflow for at least 10 sec during sleep that is accompanied by either a 3% desaturation or an arousal. (Harrison’s 19th edition, pp 1725)
Hypopnea
Standard medical therapy with the highest level of evidence for efficacy. (Harrison’s 19th edition, pp 1727)
CPAP
Side effects of Continuous Positive Airway Pressure (CPAP). (Harrison’s 19th edition, pp 1727)
Nasal Congestion Claustrophobia Difficulty exhaling Bruised nasal ridge Aerophagia
Risk for cardiovascular, cerebrovascular and metabolic diseases that OSAHS significantly increases. (Harrison’s 19th edition, pp 1726)
Coronary artery disease Heart failure (with or without reduced ejection fraction) Atrial and ventricular arrhythmias Atherosclerosis Stroke Diabetes
Treatment for nasal congestion due to CPAP. (Harrison’s 19th edition, pp 1727)
Provide heated humidification
Administer saline/steroid nasal sprays
Treatment for claustrophobia due to CPAP. (Harrison’s 19th edition, pp 1727)
Change mask interface (to nasal prongs) Promote habituation (practice breathing on CPAP while awake)
Factors for residual sleepiness. (Harrison’s 19th edition, pp 1726)
Suboptimal treatment adherence
Insufficient sleep time
Other sleep disorders
Prior hypoxic-mediated damage in the brain (areas involved in alertness)
Somnogenic cytokines (from visceral adipose tissue)
Treatment for difficulty of exhaling due to CPAP. (Harrison’s 19th edition, pp 1727)
Temporarily reduce pressure
Provide bilevel positive airway pressure